Understanding the costs of drug-related actions is an important aspect of drug policy. Some of the funds allocated by governments to expenditure on tasks related to drugs are identified as such in the budget (‘labelled’). Often, however, most drug-related expenditure is not identified (‘unlabelled’) and must be estimated using modelling approaches.
Although the financing of drug-related activities in Bulgaria is decided annually by the entities in charge of their implementation, coordination between central and local government plays an important role. In addition, according to the National Anti-Drug Strategies (for both 2009-13 and 2014-18), national programming documents have been important guides for the planning of public financing for drug-related initiatives. Estimates for drug-related public expenditure are reported; however, it is not possible to assess what proportion of the total amount spent is represented by those estimates. Preliminary estimates indicate that, in 2015, a total of BGN 3 892 496 (EUR 1 990 232) was allocated for labelled drug-related expenditure, which represented about 0.01 % of gross domestic product.